Internal Report 21: “Women Suffered 94% of Dermatological Adverse Events Reported in First 90 Days of Pfizer COVID “Vaccine” Rollout. 80% of These Adverse Events Were Categorized As ‘Serious.’”

The WarRoom/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1)—Barbara Gehrett, MD; Joseph Gehrett, MD; Chris Flowers, MD; and Loree Britt—produced a report about Dermatological Adverse Events of Special Interest (AESIs) found in Pfizer document 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021 (a.k.a., “5.3.6”). This category of AESIs contains two diagnoses and 20 adverse event reports. It is important to note that the AESIs in the 5.3.6 document were reported to Pfizer for only a 90-day period starting on December 1, 2020, the date of the United Kingdom’s public rollout of Pfizer’s COVID-19 experimental mRNA “vaccine” product. Key points of this report include:

• The two dermatological diagnoses in the report are erythema multiforme, a distinctive hypersensitivity reaction with target-like lesions involving the skin and mucous membranes, and chilblains, a localized form of vasculitis affecting mainly fingers and toes.
• There were 13 erythema multiforme adverse events, and seven chilblains adverse events.
• Eighteen of the adverse events occurred in adults and just one in the elderly age group. Age was not provided on the remaining case.
• Seventeen (94%) of the affected individuals were female. One was male, and one was of unknown sex.
• The two remarkable features of this small group of patients are the overwhelming ratio of female to male and the occurrence in nonelderly adults.
• The median onset was three days after the injection, ranging from under 24 hours to 17 days. Outcomes reported included seven “resolved/resolving,” eight “not resolved,” and six “unknown.” Note: Pfizer’s 5.3.6 document shows 20 cases (patients) and 20 adverse events; however, both sex and outcomes in Pfizer’s document do not add up to 20. Rather, sex is fewer than 20 (19), and outcomes are more than 20 (21).
• Despite erythema multiforme being an immune-mediated reaction, Pfizer chose not to include it in the Immune-Mediated/Autoimmune AESI category, which had over 500 hypersensitivity adverse events.
• Chilblains is a type of vasculitis, yet these adverse events were not reported under Pfizer’s “Vasculitis category” of AESIs.

[IMAGE 1 — ORIGINAL SOURCE PAGE 283; PLACE AFTER THE TEXT ABOVE]

•Sixteen (80%) of these adverse events were categorized as serious. According to the FDA, serious adverse events include, but are not limited to, patient outcomes such as death, life-threatening events, hospitalizations, and disability or permanent damage.

• Pfizer concludes: “This cumulative case review does not raise new safety issues. Surveillance will continue.”

Please read the full report below.

[IMAGE 2 — ORIGINAL SOURCE PAGE 284; PLACE AFTER THE TEXT ABOVE]

(https://dailyclout.io/wp-content/uploads/Post-Marketing-Dermatological-AESI-micro-report.pdf )

[IMAGE 3 — ORIGINAL SOURCE PAGE 285; PLACE AFTER THE TEXT ABOVE]